Markets

Dr Reddy's Labs Q3 Results: Profit dips 14% YoY to ₹1210 crore; revenue grows 4%

January 21, 2026

Dr Reddy's Labs Q3 Results: Dr Reddy's Laboratories (DRL) on Wednesday, January 21, posted a 14% decline in the consolidated net profit during the third quarter of the financial year 2025-26 (Q3FY26). The pharma major, part of the Nifty 50 index, said its net profit stood at ₹1209.8 crore in Q3 FY26 as against ₹1413.3 crore in the same period a year ago. However, analysts, on average, had estimated profit to fall to ₹1070 crore, as per data compiled by LSEG, showed a Reuters report.

Dr Reddy's Labs Q3 Results: Profit dips 14% YoY to ₹1210 crore; revenue grows 4%

Credit: Livemint

Key Highlights

Its revenue from operations rose 4.4% to ₹8726.8 crore in the quarter under review compared with ₹8358.6 crore in Q3FY25.
On the operating front, Dr Reddy's Labs' EBITDA declined 10.8% YoY to ₹2049.3 crore.
The gross margins moderated to 53.6% in Q3FY26 from 58.7% in Q3FY25 and 54.7% in Q2FY26, according to the press release.
Growth was broad-based across key markets, except for North America Generics, which reported a decline primarily on account of lower Lenalidomide sales, the company said.
Growth was further aided by favourable foreign exchange rate movements.

Sources

Dr Reddy's Labs Q3 Results: Profit dips 14% YoY to ₹1210 crore; revenue grows 4%

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Dr Reddy's Labs Q3 Results: Profit dips 14% YoY to ₹1210 crore; revenue grows 4%

Key Highlights

Sources

Related Stories

Will rare-earth pivot extend Nalco’s rally, or end it?

Significant fall in government borrowing in December, figures show

Stocks Plunge on Greenland Crisis and Soaring Bond Yields